A prospective case series of Ranibizumab for the treatment of inflammatory and idiopathic choroidal neovascular membranes.
Phase of Trial: Phase II
Latest Information Update: 31 May 2017
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 31 May 2017 New trial record
- 01 Sep 2016 Status changed from recruiting to completed, according to results published in the British Journal of Ophthalmology.